Overview
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Eligibility
Inclusion Criteria:
- Pregnant people prior to 17 weeks
- Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
- Age 18-50 years
- Singleton viable gestation
- Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.
Exclusion Criteria:
- Undergoing glucose challenge test (GCT) at time of blood draw
- Allergy or intolerance to aspirin
- Antithrombotic or antiplatelet therapy
- Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (platelet count \<100,000), or thrombocytosis (platelet count \>600,000)
- Known hemorrhagic diathesis
- Planned delivery outside of NYU
